BAG3 and cancer: Despite differences in the chemical properties of bortezomib, MG-132, and MLN-2238, treatment with these PIs led to the recurrent dysregulation of 12 genes (e.g. BAG3, DNAJB1, HMOX1) in cell lines representing multiple cancer types.